Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer
2020 · Journal of Oncology Pharmacy Practice · 10 citations
https://doi.org/10.1177/1078155220924088
S
Serdar Arıcı
Okan University(TR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
43
Papers
228
Citations
10
h-index
11
i10-index
Serdar Arıcı is an academic researcher from Okan University. The author has contributed to research in topics: Metastasis and carcinoma case studies & Inflammatory Biomarkers in Disease Prognosis & Lung Cancer Research Studies. The author has an h-index of 10, co-authored 37 publications.
ORCID: 0000-0003-2018-6554Papers by this author
worksCan 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
2021 · Nuclear Medicine Communications · 7 citations
https://doi.org/10.1097/mnm.0000000000001431
The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy
2021 · Cureus · 3 citations
https://doi.org/10.7759/cureus.14639
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
2024 · Current Problems in Cancer · 3 citations
https://doi.org/10.1016/j.currproblcancer.2024.101102
Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome
2024 · Indian Journal of Cancer · 2 citations
https://doi.org/10.4103/ijc.ijc_1283_20
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat